Concord Biotech shareholding pattern

·Pharma & HealthChart ›

Who owns itSep 2026 quarter

Promoters44.09%+0.01 pts
Foreign investors (FII)7.28%−0.24 pts
Domestic institutions (DII)10.95%+1.59 pts
of which mutual funds5.84%+1.44 pts
of which insurance companies4.26%
Public37.68%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,268.50

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹13,271 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group44.0844.0844.0844.0844.0844.0844.0844.0844.0844.09
FII / FPI7.118.108.339.359.118.037.587.807.527.28
DII10.409.899.669.168.879.559.589.229.3610.95
Mutual Funds5.264.974.865.164.684.534.444.304.405.84
Latest: 2026-09-30 · 13 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.